Dyne Therapeutics, Inc.
DYN · Healthcare · $3.0B
Pre-market $16.30+1.18%
Price
$23.07
$16.21
Jul 2, 26Sep 29, 26
What's this stock's score right now?
See its score for free — revenue and money flow, graded on one standard.
Quarterly Financials
RevenueOperating IncomeNet Income
9/'26
Revenue$0M
6/'26 vs prev quarter
Company Health
Market Cap$3.0B
Cash on Hand$898M29.9% of market cap
Free Cash Flow$-499M-16.6% of market cap
Among 463 Biotechnology peers
LowMedianHigh
PBR4.3xmedian 2.0xROE-74.0%median -54.5%Dyne Therapeutics Remains A Buy Even As Novartis Trial Failure Hits DM1 ClassSep 9
Stock Traders Buy High Volume of Dyne Therapeutics Call Options (NASDAQ:DYN)Sep 9
Novartis Myotonic Dystrophy Trial Flop Sends Dyne Therapeutics Shares TumblingSep 8
Dyne Therapeutics to Present Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) at Upcoming Medical MeetingsSep 8
Dyne Therapeutics, Inc. $DYN is Atlas Venture Life Science Advisors LLC’s 2nd Largest PositionSep 4
Dyne Therapeutics to Present Preclinical Data for Multiple Development Candidates for Duchenne Muscular Dystrophy (DMD) at 27th Annual NMSG Scientific MeetingSep 3
